Stopped: Paused while the study is transferred from Baylor College of Medicine to Texas A\&M University.
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relative importance of GBP to antidepressant symptom reduction across the induction phase of treatment. If successful, it provides a compelling rationale for a larger prospective investigation of gamma dynamics as a moderator of outcome to varied TRD therapies which impact the balance of cortical excitation and inhibition.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Resting State Gamma Power
Timeframe: Before infusion, during infusion, 60-90 minutes after infusion
Auditory Steady State Response Gamma Power
Timeframe: Before infusion, during infusion, 60-90 minutes after infusion
Montgomery-Asberg Depression Rating Scale (MADRS)
Timeframe: Study entry, pre-infusion, study exit visit (up to a month after infusion)